Know Cancer

or
forgot password

Impact of the OncoDoc2 Decision Support System on Compliance of Multidisciplinary Staff Meeting Decisions With Clinical Practice Guidelines in the Management of Non-metastatic Breast Cancer.


N/A
N/A
N/A
Open (Enrolling)
Female
Breast Cancer

Thank you

Trial Information

Impact of the OncoDoc2 Decision Support System on Compliance of Multidisciplinary Staff Meeting Decisions With Clinical Practice Guidelines in the Management of Non-metastatic Breast Cancer.


In France, to promote the quality of cancer care, decisions have currently to be made
according to clinical practice guidelines (CPGs) during regularly organized
multidisciplinary staff meetings (MSMs). Dissemination of textual CPGs has a poor impact on
clinical practice as opposed to the use of clinical decision support systems (CDSSs) known
to improve compliance with CPGs. OncoDoc2 is a CDSS providing patient-specific
recommendations based on CPGs for non-metastatic female breast cancer management elaborated
by the CancerEst INTERMEDICAL collaboration.The main goal of the study is to evaluate the
effect of the routine use of OncoDoc2 during MSMs on compliance of MSM decisions with local
CPGs. Impact will be measured by the compliance rate of MSM decisions with OncoDoc2
recommendations. The design of the study relies on a cluster randomized controlled trial.
Under the assumption of a baseline compliance rate of 70% without intervention, an expected
compliance rate of 90% in the intervention group (α = 5%, β = 20%), an inter-cluster
variability of 5%, and 59 decisions per center, the required number of centers is 3 in each
group, or 177 decisions in each arm. The study will be conducted in cancer care centers
(public and private) from Paris area, France.This prospective trial will be conducted in two
steps. First, baseline compliance rates will be measured in each center. Then, the 6 centers
will be randomized into 2 arms. In the intervention arm, OncoDoc2 will be used during MSMs
at decision time. Every case of non-adherence with system recommendations will have to be
justified by clinicians. In both arms and after each MSM, MSM decisions will be recorded as
well as patient characteristics and OncoDoc2 will be used for each patient case to get
system recommendations. In the intervention arm, OncoDoc2 recommendations obtained by MSM
will also be recorded, as well as the reason for non following recommendations in case MSM
decision does not comply with guidelines.


Inclusion Criteria:



- Non metastatic, including invasive and in situ, breast cancers as well as axillary
cancer without breast tumor.

- At least one therapeutic MSM decision.

Exclusion Criteria:

- Breast disease without cancer

- Metastatic breast cancer

- Male breast cancer

- Breast cancer cases when medical records are not accessible to investigators

- Management but not therapeutic breast cancer decisions (diagnostic investigations,
treatment follow-up, delayed decisions…)

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label

Outcome Measure:

Compliance of multidisciplinary staff meeting (MSM) decisions with OncoDoc2 guideline-based recommendations at one year : MSM decisions are recorded on a weekly basis.

Outcome Time Frame:

Every week

Safety Issue:

No

Principal Investigator

Serge UZAN, MD, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Assistance Publique - Hôpitaux de Paris

Authority:

France: French Data Protection Authority

Study ID:

K 070603

NCT ID:

NCT00728442

Start Date:

December 2008

Completion Date:

March 2011

Related Keywords:

  • Breast Cancer
  • Clinical practice guidelines
  • Guideline adherence
  • Clinical decision support systems
  • Randomized controlled trial
  • Intervention study
  • Breast Neoplasms

Name

Location